Clinical Rheumatology
https://doi.org/10.1007/s10067-019-04694-z

ORIGINAL ARTICLE

The expression of GAS5, THRIL, and RMRP lncRNAs is increased in T cells of patients with rheumatoid arthritis

Mozhgan Moharamoghli[1] · Vahideh Hassan-Zadeh[1] · Elahe Dolatshahi[2] · Zahra Alizadeh[3] · Ali Farazmand[1]

Received: 19 May 2019 / Revised: 4 July 2019 / Accepted: 12 July 2019

Abstract

Objective Long non-coding RNAs (lncRNAs) comprise a large and diverse group of non-coding RNAs (ncRNAs) with important regulatory roles in various biological processes, including the immune system regulation. Rheumatoid arthritis (RA) as an autoimmune disease initiates inflammation in the synovial joints. T cells infiltrating into the synovial membrane have an important role in the pathogenesis of RA. The aim of the current investigation was to analyze the expression of four lncRNAs in the T cells from RA patients and healthy controls.

Methods In the current study, we investigated the expression of GAS5, RMRP, IFNϒ-AS1, and THRIL lncRNAs in circulating T cells from 20 patients with RA and 18 healthy matched controls by quantitative real-time PCR. T cell isolation was accomplished using the MAC method. We also analyzed the correlation between lncRNA expression and clinical parameters. Also, the mRNA expression levels of IL-17 and TNF-α and the association between lncRNAs and these cytokines were examined.

Results The results indicate that T cells of RA patients display increased levels of GAS5 (3.31-fold, $p = 0.007$), RMRP (2.43-fold, $p = 0.02$), and THRIL (2.14-fold, $p = 0.03$) lncRNAs compared with those of controls. Furthermore, a positive correlation was found between RMRP expression and disease duration in RA. Receiver operating characteristic (ROC) curve of GAS5, RMRP, and THRIL has a discriminative value in comparing RA patients and controls.

Conclusion The results suggest lncRNAs may be involved in T cell dysfunction in RA. Further studies are required to see whether these lncRNAs have an effect on dysregulation of immune responses in RA disease.

Key Points

- *70% of non-coding sequences in the human genome are transcribed to RNA.*
- *A growing body of evidence shows the importance of lncRNAs in innate and adaptive immune cell differentiation and functions.*
- *Important recent works suggest a key role of immune cell lncRNAs in autoimmune processes and diseases including RA.*

Keywords GAS5 · IFNϒ-AS1 · lncRNA · Rheumatoid arthritis · RMRP · THRIL

Introduction

Rheumatoid arthritis (RA) is a systemic inflammatory disease affecting the joints and leads to the destruction of the synovial membrane and cartilage and bone erosion [1]. In severe cases, RA is accompanied by extra-articular manifestations and the involvement of other internal organs of the body leading to disability and death. RA is known as one of the most common autoimmune diseases, affecting about 1% of the population worldwide. The disease is 2 to 4 times more prevalent among women [2]. Epidemiological studies demonstrated that the peak age of the disease is around the fourth decade of life [3]. Similar

✉ Ali Farazmand
afarazmand@ut.ac.ir

[1] Department of Cell and Molecular Biology, School of Biology, Faculty of Science, College of Science, University of Tehran, Tehran, Iran

[2] Department of Rheumatology, Alborz University of Medical Science, Karaj, Iran

[3] Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran

Published online: 25 July 2019

to the most autoimmune diseases, RA is a multifactorial disease affected by both genetic and environmental factors [4]. The studies on identical twins demonstrated that genetic factors are responsible for 60% liability to the RA disease indicating the importance of environmental factors (such as smoking and infection) [5]. The variants of several genes, particularly *HLA-DRB1*, have been demonstrated to increase the risk of RA [6].

Previously, B lymphocytes and immunoglobulins were considered the most important actors in RA pathogenesis [7]. However, new studies point at the importance of macrophages, T cells, and resident synovial membrane cells and their cytokines in the initiation and the development of inflammation and tissue damage [8]. It is known that some T cell subsets such as Th1, Th17, and Treg are involved in the pathogenesis of the RA [9]. Th17 cells through the production of IL-17 have been implicated in RA. For instance, the combination of the anti-TNF-α and monoclonal antibodies against IL-17 cytokine showed more efficacy in disease treatment [10]. The anti TNF-α is an effective biological agent for RA patient treatment. Recently new Treg-manipulating approaches have provided promising results in the treatment of RA in pre-clinical models [11, 12]. Besides, the strong association between class II MHC and the development of RA indicates the importance of T cells in RA.

Non-coding RNAs (ncRNA) are a group of RNA molecules that code no proteins. Non-coding RNAs, based on their length, are divided into two groups: short ncRNAs and long non-coding RNAs (lncRNA) [13]. Short ncRNAs such as micro-RNAs, piwi-interacting RNAs, small nucleolar RNAs, and many others encompass less than 200 nucleotides. lncRNAs are a type of ncRNAs with a length of more than 200 nucleotides that mostly are transcribed by RNA polymerase II, which subsequently are capped, spliced, and polyadenylated [14]. lncRNAs are categorized in different classes based on their genomic location, including intergenic non-coding RNAs (lincRNAs), natural antisense transcripts (NATs), and intronic lncRNAs [15]. lncRNAs have different biological functions from epigenetic regulation to protein metabolism through interactions with DNA, RNA, and proteins. Many studies have reported the key role of lncRNAs in the regulation of gene expression, differentiation, and development of innate and adaptive immune cells [16, 17]. T cells, as one of the components of the adaptive immune system, express specific lncRNAs to regulate their function [18]. Recently, dysregulation of lncRNAs in various autoimmune diseases, including RA, has been reported [19]. In the present study, we investigated the expression of lncRNAs including growth arrest specific 5 (GAS5), the RNA component of mitochondrial RNA processing endoribonuclease (RMRP), TNF-α- and hnRNPL-related immunoregulatory lincRNA (THRIL), and interferon gamma antisense RNA 1 (IFNϒ-AS1) in circulating T cells from RA patients. Moreover, the association between the expression of these lncRNAs, clinical manifestations of the disease, and two important cytokines, TNF-α and IL-17, involved in the disease was examined.

Materials and methods

Patients and control participants

In this study, 20 RA patients and 18 sex- and age-matched healthy controls were enrolled. Patient diagnostics were accomplished by a rheumatologist based on the American College of Rheumatology (ACR) criteria for RA [20]. The control subjects enrolled in current project were not affected by any autoimmune or rheumatic diseases nor did have a family history of any autoimmune disease. Informed consent was obtained from all participants. All steps are performed according to the revised ethical principles of the Declaration of Helsinki in 2000. Control and patient's clinical and demographic information is presented in more detail in Table 1. Clinical parameters including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and disease activity scores of 28 joints (DAS-28) were measured after blood withdrawal. RA patients were receiving methotrexate and prednisolone drugs but not anti-TNF-α treatment.

T cell isolation and RNA extraction

Peripheral blood was taken from the participants. Two milliliters of the blood was used to measure ESR, and 4 ml of blood serum was extracted for determining rheumatoid factor (RF) and CRP. Peripheral blood mononuclear cells (PBMCs) were obtained from 7 ml blood using Ficoll (Lympholyte-H, Cedarlane, Canada, CL5020) density gradient centrifugation. T cells were purified from PBMCs by negative selection using a magnetic-activated cell (MAC) isolation kit and magnetic-activated cell sorter columns (all from Miltenyi Biotec, Germany, cat no 130-042-401), according to the manufacturer's instructions. Total RNA was extracted by RiboEx™

Table 1 Clinical characteristics of RA patients and healthy controls

Characteristics	RA patients ($n = 20$)	Healthy controls ($n = 18$)
Male/female	16 (80%)/4 (20%)	14 (70%)/4 (30%)
Age (years)	48 ± 11.98	45 ± 9.03
ESR (mm/h)	23.65 ± 18.72	NA
CRP (μg/ml)	17.54 ± 15.86	NA
DAS-28 ESR score	4.21 ± 1.27	NA
Disease duration	8.25 ± 4.19	NA
Medication (no. of patients)		
Methotrexate	20	0
Prednisolone	20	0
Biological agents	0	0

RA rheumatoid arthritis, *ESR* erythrocyte sedimentation rate, *CRP* C-reactive protein, *DAS-28 ESR* Disease Activity Score-28 erythrocyte sedimentation rate, *NA* not applicable

(GeneAll, Korea, cat no. 301-902). Purity and concentration of isolated RNA were determined with a nano-spectrophotometer (NanoDrop Technologies, USA).

cDNA synthesis and real-time PCR

Two micrograms of RNA was used for complementary DNA (cDNA) synthesis by 2x RT pre-mix (Biofact, Korea, BR631-096) and random hexamers. Gene expression analysis was carried out using the 2X Real-Time PCR Master Mix (Biofact™, Korea, cat no. DQ383-40H) and the Magnetic Induction Cycler real-time PCR apparatus system (Bio Molecular Systems, Australia). The *B2M* gene was used for normalization. Primers for the genes were designed and blasted using the Primer3 online software and the National Center for Biotechnology Information (NCBI) database. Primer sequences are shown in Table 2. The comparative CT method ($2^{-\Delta CT}$) was used to analyze the relative changes in mRNA expression.

Statistical analysis

All statistical analyses were performed using SPSS version 16 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 6. Data distribution was identified by the Shapiro–Wilk test. The Mann–Whitney *U* test was used for the analysis of the relative gene expression. Correlation between clinical parameters and relative gene expression was tested with the Spearman correlation test. The receiver operating characteristic (ROC) curve was plotted to assess the dysregulated THRIL, IFNϒ-AS1, RMRP, and GAS5 lncRNAs for RA diagnosis. *p* values less than 0.05 were considered significant.

Table 2 Primer sequences and product size of the selected genes

Gene	Primer	Sequence (5′–3′)
GAS5	Forward	CTTCTGGGCTCAAGTGATCCT
	Reverse	TTGTGCCATGAGACTCCATC AG
RMRP	Forward	ACTCTGTTCCTCCCCTTTCC
	Reverse	CTTCTTGGCGGACTTTGGAG
THRIL	Forward	GGTGATCCATACTCCTCGGC
	Reverse	TGGGCAAGGGAGTTTCAGAA
IFNϒ-AS1	Forward	ACGAACTAGCACAACGAGG
	Reverse	TGACTTCTCCTCCAGCGTTT
IFN-ϒ	Forward	TCCTTTGGACCTGATCAGCT
	Reverse	TATGGGTCCTGGCAGTAACA
IL-17	Forward	TGTGATCTGGGAGGCAAAGT
	Reverse	CCCACCGGACACCAGTATCTT
TNF-α	Forward	AGGACCAGCTAAGAGGGAGA
	Revers	CCCGGATCATGCTTTCAGTG
B2m	Forward	CCTGAATTGCTATGTGTCTG
	Reverse	TGATGCTGCTTACATGTCTCGA

Result

In order to study the expression of four lncRNAs, 20 RA patients along with 18 age- and sex-matched healthy controls were employed. In this study, according to DAS-28 data, patients were divided into two groups: severely (DAS-28 > 5) and mildly (5.1 > DAS-28 > 3.2) affected patients. The expression of the four selected lncRNAs (GAS5, RMRP, IFNϒ-AS1, and THRIL) was measured in isolated T cells from RA patients and controls using the quantitative real-time PCR method. The results show a significant increase in the levels of GAS5 with 3.31-fold change ($p = 0.007$), RMRP with 2.43-fold change ($p = 0.02$), and THRIL with 2.14-fold change ($p = 0.03$) in RA patients in comparison with controls (Fig. 1). The results show no significant changes in IFNϒ-AS1 expression ($p > 0.05$) between RA patient T cells and healthy subjects.

Next, we studied the association between the expression of lncRNAs and RA clinical manifestations. Clinical parameters included DAS-28, ESR, CRP, age, and disease duration. We found a positive correlation between RMRP lncRNA expression and disease duration ($p = 0.04$, $r = 0.59$) using the Spearman correlation test (Fig. 2). There was no significant association between lncRNA expression and clinical parameters.

TNF-α and IL-17 are two important cytokines produced by T cells involved in RA disease. We measured the expression of these two cytokines in T cells of RA patients in comparison with healthy controls. TNF-α and IL-17 expression showed a 3.02-fold ($p = 0.04$) and 2.86-fold ($p = 0.01$) increase in T cells of RA versus controls (Fig. 1e, f). Then, we examined whether there was a correlation between these cytokine expressions and the expressions of lncRNAs (Fig. 3a–f). There was no correlation between the expression of lncRNAs and TNF-α and IL-17 expression.

The ROC curve was drawn to evaluate the diagnostic value of GAS5, RMRP, IFNG-AS1, and THRIL lncRNAs in RA disease. The area under the curve (AUC) of GAS5, RMRP, and THRIL were 0.75 (95% CI 0.59–0.92, $p = 0.006$), 0.71 (95% CI 0.55–0.88, $p = 0.02$), and 0.7(95% CI 0.52–0.87, $p = 0.03$), respectively (Fig. 4). This indicates a clear distinction between the RA and control groups and could provide better diagnostic efficiency. However, IFNG-AS1 lncRNA with an AUC 0.61 (95% CI 0.41–0.82) and a *p* value of 0.2 lacked a predictive value for RA (Fig. 4).

Discussion

Around 2% of the human genome comprises protein-coding genes, and at least around 70% of non-coding sequences are



Fig. 1 The selected lncRNA expression in T cells of RA vs healthy controls. A significant increase in the relative expression of RMRP (2.43-fold change, $p = 0.02$) (**a**), THRIL (2.14-fold change, $p = 0.03$) (**b**), GAS5 (3.31-fold change, $p = 0.007$) (**c**), TNF-α (3.02-fold change, $p = 0.04$) (**e**), and IL-17 (2.86-fold change, $p = 0.01$) (**f**) was observed. Data are shown as the mean ± SEM. The Mann–Whitney *U* test was carried out, and *p* values below 0.05 were considered significant



Fig. 2 Correlation between disease duration and RMRP expression. The Spearman test showed a positive correlation between RMRP expression and disease duration ($r = 0.59$, $p = 0.04$). p, p value; r, Spearman rank correlation coefficient

transcribed to RNA [21]. The most common of these ncRNAs are lncRNAs. The early findings on the existence and importance of lncRNA in immune cells derived from the study of inflammation in the innate immune system [22]. A growing body of evidence shows that adaptive immune cells including T lymphocytes express many lncRNAs in any phase of their development, differentiation, and activation. lncRNAs are versatile gene expression regulators indicating they regulate gene expression at different levels including transcription, post-transcription, translation, and post-translation and are involved in epigenetic modifications [23]. Important recent works suggest a key role of immune cell lncRNAs in autoimmune processes and diseases [24]. The most important lncRNAs in RA which are known to be deregulated include HOTAIR and H19 [25–27]. The higher expression of HOTAIR has been demonstrated in PBMCs and synovial fibroblasts and in serum exosomes of patients with RA. As such, H19 is highly expressed in the synovial tissue and it is suggested that H19 participates in inflammation and joint damage [27]. Despite the apparent importance of lncRNAs, our understanding about the role of lncRNAs in RA is still in its infancy. In this study, the expression of GAS5, RMRP, IFNϒ-AS1, and THRIL lncRNAs was analyzed for the first time in T cells of RA patients. Our finding indicates a significant increase in the expression of GAS5, THRIL, and RMRP in T cells of RA patients. We also measured the mRNA expression of TNF-α and IL-17 produced by T cells which both showed a significant increase in T cells of RA patients. Next, we investigated the association between the expression levels of lncRNAs and clinical parameters and expression levels of cytokines.

GAS5 is a lncRNA that was first identified as a tumor suppressor gene in cancer [28]. The studies have shown aberrant expression of GAS5 in several cancers and implicated this gene in cell cycle inhibition and apoptosis [29]. Notably, it has been reported that GAS5 acts as a repressor of glucocorticoid receptors (GRs) [30]. Glucocorticoids (GC) are most effective drugs used to treat inflammatory diseases. Evidence suggests that GAS5 binds to the DNA binding domain of glucocorticoid receptors and prevents GRs from interacting with DNA [30]. One can hypothesize that the observed increased expression of GAS5 in immune cells would prevent glucocorticoid activity and thereby contribute to the development of autoimmune diseases including RA. On the other hand, higher level of GAS5 may contribute to the resistance of GC treatment in RA and other diseases [31]. Also, we did not find any meaningful association between the expression of TNF-α and IL-17 cytokines and the GAS5 expression.

The lncRNA RMRP was first identified as part of the mitochondrial enzymatic complex that cleaves mitochondrial RNAs [32]. Increasing evidence shows that the expression of RMRP is deregulated in several cancers including lung adenocarcinoma and gastric cancer [33, 34]. More recently, RMRP is identified as a partner of RORϒt transcription factor in Th17cells [35]. RORϒt regulates Th17 differentiation and transcription of selective Th17 genes including IL-17 and demonstrated to be needed for inflammatory pathologies caused by Th17 cells [35]. Huang et al. discovered that RMRP, along with a RNA helicase called DDX, is required for promoting assembly and regulating RORϒ transcriptional activity in Th17 cells [35]. IL-17 produced by Th17 cells has strong proinflammatory and joint-destructive activities [10, 36]. Here there was a significant increase in RMRP and IL-17 levels; nonetheless, no significant correlation was found between them. There was also a significant correlation between the expression of RMRP and the duration of the disease.

IFNϒ-AS1, also known as Tmevpg1 and NeST, is mapped adjacent to the interferon (IFN)-ϒ-encoding gene in both human and mouse genomes [37]. It has been shown that IFNϒ-AS1 is involved in regulating IFNϒ expression and expressed selectively in Th1 cells. Important recent works suggest that IFNϒ-AS1 may have proinflammatory properties. It was indicated that lncRNA IFNϒ-AS1 contributes to the inflammatory responses in other autoimmune diseases myasthenia gravis and Hashimoto's thyroiditis [38, 39]. The cytokine IFNϒ has an important role in inflammation and cell death [40]. We hypothesized that based on the importance of IFNϒ in RA, IFNϒ-AS1 may also be involved in the disease. But our results showed no significant differences in the IFNϒ-AS1 level between RA and control subjects.

THRIL is the last lncRNA that was investigated in this study. Recently, a study by Li et al. [41] has revealed that THRIL forms an RNA-protein complex with heterogenous nuclear ribonucleoprotein L (hnRNPL) and regulates TNF-α expression in the innate immune system. Their data showed that THRIL knockdown leads to the dysregulation of many immune-associated genes. It was also reported that THRIL



Fig. 3 The correlation between lncRNAs and TNF-α and IL-17 cytokine expression. The correlation was measured using the Spearman test (**a**–**f**). *p* values < 0.05 were considered significant

expression in PBMCs of Kawasaki patients was associated with the severity of symptoms [42]. The role of TNF-α in RA disease is obvious. Here our finding indicates a significant increase in T cells of RA individuals. But we observed no correlation between THRIL expression and TNF-α and clinical parameters of RA patients.

The current study, for the first time, indicates the expression of GAS5, RMRP, and THRIL lncRNAs in T cells of RA



Fig. 4 The ROC curve of GAS5, IFNG-AS1, RMRP, and THRIL expression levels in T cells for RA diagnosis. The ROC curve showed that GAS5 (AUC 0.75, 95% CI 0.59–0.92, $p = 0.006$), RMRP (AUC 0.71, 95% CI 0.55–0.88, $p = 0.02$), and THRIL (AUC 0.7, 95% CI 0.52–0.87, $p = 0.03$) had good diagnostic efficacy

patient. Also, it shows a positive correlation between RMRP expression and disease duration in RA. Further studies are required to ask whether lncRNAs examined in the current study are involved in the pathogenesis of RA.

Compliance with ethical standards

Disclosure None.

References

1. Klareskog L, Catrina AI, Paget S (2009) Rheumatoid arthritis. Lancet 373(9664):659–672. https://doi.org/10.1016/s0140-6736(09)60008-8
2. Kourilovitch M, Galarza-Maldonado C, Ortiz-Prado E (2014) Diagnosis and classification of rheumatoid arthritis. J Autoimmun 49:26–30
3. Khurana R, Berney SM Clinical aspects of rheumatoid arthritis. Pathophysiology 12(3):153–165. https://doi.org/10.1016/j.pathophys.2005.07.009
4. Croia C, Bursi R, Sutera D, Petrelli F, Alunno A, Puxeddu I (2019) One year in review 2019: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 37(3):347–357
5. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ (2000) Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 43(1):30–37
6. Pratt AG, Isaacs JD, Mattey DL (2009) Current concepts in the pathogenesis of early rheumatoid arthritis. Best Pract Res Clin Rheumatol 23(1):37–48. https://doi.org/10.1016/j.berh.2008.08.002
7. Bennett JC (2008) The role of T lymphocytes in rheumatoid arthritis and other autoimmune diseases. Arthritis Rheum 58(S2):S53–S57. https://doi.org/10.1002/art.23045
8. Cope AP, Schulze-Koops H, Aringer M (2007) The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol 25(5 Suppl 46):S4–S11
9. Lubberts E (2015) Role of T lymphocytes in the development of rheumatoid arthritis. Implications for treatment. Curr Pharm Des 21(2):142–146
10. Gaffen SL (2009) The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep 11(5):365–370

11. Boissier MC, Assier E, Biton J, Denys A, Falgarone G, Bessis N (2009) Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine 76(1):10–14
12. Leipe J, Skapenko A, Lipsky PE, Schulze-Koops H (2005) Regulatory T cells in rheumatoid arthritis. Arthritis Res Ther 7(3): 93–93. https://doi.org/10.1186/ar1718
13. Gomes AQ, Nolasco S, Soares H (2013) Non-coding RNAs: multi-tasking molecules in the cell. Int J Mol Sci 14(8):16010–16039. https://doi.org/10.3390/ijms140816010
14. Mercer TR, Dinger ME, Mattick JS (2009) Long non-coding RNAs: insights into functions. Nat Rev Genet 10(3):155–159
15. Mowel WK, Kotzin JJ, McCright SJ, Neal VD, Henao-Mejia J (2018) Control of immune cell homeostasis and function by lncRNAs. Trends Immunol 39(1):55–69
16. Chen YG, Satpathy AT, Chang HY (2017) Gene regulation in the immune system by long noncoding RNAs. Nat Immunol 18(9): 962–972
17. Heward JA, Lindsay MA (2014) Long non-coding RNAs in the regulation of the immune response. Trends Immunol 35(9):408–419
18. Aune TM, Crooke PS 3rd, Spurlock CF 3rd (2016) Long noncoding RNAs in T lymphocytes. J Leukoc Biol 99(1):31–44
19. Wu G-C, Pan H-F, Leng R-X, Wang D-G, Li X-P, Li X-M, Ye D-Q (2015) Emerging role of long noncoding RNAs in autoimmune diseases. Autoimmun Rev 14(9):798–805. https://doi.org/10.1016/j.autrev.2015.05.004
20. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JMW, Hobbs K, Huizinga TWJ, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581. https://doi.org/10.1002/art.27584
21. Mowel WK, Kotzin JJ, McCright SJ, Neal VD, Henao-Mejia J (2018) Control of immune cell homeostasis and function by lncRNAs. Trends Immunol 39(1):55–69. https://doi.org/10.1016/j.it.2017.08.009
22. Zhang Y, Cao X (2016) Long noncoding RNAs in innate immunity. Cell Mol Immunol 13(2):138–147. https://doi.org/10.1038/cmi.2015.68
23. Tang Y, Zhou T, Yu X, Xue Z, Shen N (2017) The role of long non-coding RNAs in rheumatic diseases. Nat Rev Rheumatol 13:657–669. https://doi.org/10.1038/nrrheum.2017.162
24. Wu GC, Pan HF, Leng RX, Wang DG, Li XP, Li XM, Ye DQ (2015) Emerging role of long noncoding RNAs in autoimmune diseases. Autoimmun Rev 14(9):798–805
25. Zhang HJ, Wei QF, Wang SJ, Zhang XY, Geng Q, Cui YH, Wang XH (2017) LncRNA HOTAIR alleviates rheumatoid arthritis by targeting miR-138 and inactivating NF-kappaB pathway. Int Immunopharmacol 50:283–290
26. Song J, Kim D, Han J, Kim Y, Lee M, Jin E-J (2015) PBMC and exosome-derived Hotair is a critical regulator and potent marker for rheumatoid arthritis. Clin Exp Med 15(1):121–126. https://doi.org/10.1007/s10238-013-0271-4
27. Stuhlmuller B, Kunisch E, Franz J, Martinez-Gamboa L, Hernandez MM, Pruss A, Ulbrich N, Erdmann VA, Burmester GR, Kinne RW (2003) Detection of oncofetal h19 RNA in rheumatoid arthritis synovial tissue. Am J Pathol 163(3):901–911
28. Pickard MR, Williams GT (2015) Molecular and cellular mechanisms of action of tumour suppressor GAS5 LncRNA. Genes 6(3): 484–499
29. Gutschner T, Diederichs S (2012) The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 9(6):703–719
30. Kino T, Hurt DE, Ichijo T, Nader N, Chrousos GP (2010) Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci Signal 3(107):2000568
31. Lucafo M, Bravin V, Tommasini A, Martelossi S, Rabach I, Ventura A, Decorti G, De Iudicibus S (2016) Differential expression of GAS5 in rapamycin-induced reversion of glucocorticoid resistance. Clin Exp Pharmacol Physiol 43(6):602–605
32. Chang DD, Clayton DA (1987) A novel endoribonuclease cleaves at a priming site of mouse mitochondrial DNA replication. EMBO J 6(2):409–417
33. Meng Q, Ren M, Li Y, Song X (2016) LncRNA-RMRP acts as an oncogene in lung cancer. PLoS One 11(12):e0164845
34. Shao Y, Ye M, Li Q, Sun W, Ye G, Zhang X, Yang Y, Xiao B, Guo J (2016) LncRNA-RMRP promotes carcinogenesis by acting as a miR-206 sponge and is used as a novel biomarker for gastric cancer. Oncotarget 7(25):37812–37824
35. Huang W, Thomas B, Flynn RA, Gavzy SJ, Wu L, Kim SV, Hall JA, Miraldi ER, Ng CP, Rigo F, Meadows S, Montoya NR, Herrera NG, Domingos AI, Rastinejad F, Myers RM, Fuller-Pace FV, Bonneau R, Chang HY, Acuto O, Littman DR (2015) DDX5 and its associated lncRNA Rmrp modulate Th17 cell effector functions. Nature 528(7583):517–522. https://doi.org/10.1038/nature16193
36. Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, Skapenko A (2010) Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 62(10):2876–2885
37. Gomez JA, Wapinski OL, Yang YW, Bureau JF, Gopinath S, Monack DM, Chang HY, Brahic M, Kirkegaard K (2013) The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-gamma locus. Cell 152(4):743–754
38. Peng H, Liu Y, Tian J, Ma J, Tang X, Rui K, Tian X, Mao C, Lu L, Xu H, Jiang P, Wang S (2015) The long noncoding RNA IFNG-AS1 promotes T helper type 1 cells response in patients with Hashimoto's thyroiditis. Sci Rep 5:17702. https://doi.org/10.1038/srep17702
39. Luo M, Liu X, Meng H, Xu L, Li Y, Li Z, Liu C, Luo Y-B, Hu B, Xue Y, Liu Y, Luo Z, Yang H (2017) IFNA-AS1 regulates CD4+ T cell activation in myasthenia gravis though HLA-DRB1. Clin Immunol 183:121–131. https://doi.org/10.1016/j.clim.2017.08.008
40. Lee SH, Kwon JY, Kim SY, Jung K, Cho ML (2017) Interferon-gamma regulates inflammatory cell death by targeting necroptosis in experimental autoimmune arthritis. Sci Rep 7(1):017–09767
41. Li Z, Chao T-C, Chang K-Y, Lin N, Patil VS, Shimizu C, Head SR, Burns JC, Rana TM (2014) The long noncoding RNA THRIL regulates TNFα expression through its interaction with hnRNPL. Proc Natl Acad Sci U S A 111(3):1002–1007. https://doi.org/10.1073/pnas.1313768111
42. Li Z, Chao TC, Chang KY, Lin N, Patil VS, Shimizu C, Head SR, Burns JC, Rana TM (2014) The long noncoding RNA THRIL regulates TNFalpha expression through its interaction with hnRNPL. Proc Natl Acad Sci U S A 111(3):1002–1007